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Introduction
Hepatocellular carcinoma (HCC) progression is accompanied by the process of immune resistance and immune evasion. Several mechanisms underlying HCC immune evasion have been associated with the tumour microenvironment, including the presence of myeloid-derived suppressor cells (MDSCs) [1, 2] . Although the suppressive function of MDSCs during liver carcinogenesis and tumour progression has been studied, a higher frequency of MDSCs correlates with an impaired anti-tumour response [3] [4] [5] [6] [7] , and the factors that regulate hepatic MDSCs accumulation in patients with HCC remain to be described.
Experimental data support the concept that accumulation of MDSCs depends largely upon the inflammatory and tumour microenvironment. Several tumour-derived inflammatory factors such as prostaglandin E 2 (PEG 2 ), interleukin (IL)-6, IL-1b, granulocyte macrophage-colonystimulating factor (GM-CSF) and proinflammatory S100 proteins play a critical role in MDSC accumulation [8] [9] [10] [11] [12] . Interestingly, recent studies have shown that MDSCs accumulate preferentially in the livers of mice bearing transplantable or chemical-inducible cancers [12, 13] . Studies also showed higher levels of MDSCs in the liver in patients with HCC. MDSCs accumulates at liver sites and regulates the immune system negatively in the milieu of the inflammation and tumour microenvironment [4, 11, 14, 15] . This effect is attributed partially to the proliferation of hepatic myeloid cells, but the migration of MDSCs into liver sites cannot be excluded. Thus, it is worth investigating the mechanisms of hepatic MDSCs accumulation or proliferation. Based on these previous studies, we hypothesized that intrinsic factors participate in the maintenance of a hepatic MDSCs reservoir.
The liver stromal microenvironment includes several cell types, including hepatic stellate cells (HSCs), endothelial cells and multiple immune cells [6, 16] . During the development of HCC, liver stromal cells contribute not only to the proliferation of tumour cells but also to the remodelling of the hepatic immune microenvironment [6, 17] . For example, one of the key players among liver stromal cells, HSCs, inhibit the T cell response by expressing co-inhibitory molecules, including B7-H1 and B7-H4, after being activated [18] [19] [20] or by interacting with immune cells to promote tumour development [17, 21] . Recently, the liver was shown to be a favourable site for MDSC accumulation in several mouse models [10, 12, 13] . Liver stromal cells secrete multiple cytokines and chemokines after activation [22] . MDSC accumulation at tumour sites is often regulated by various tumour-derived factors, including cytokines and chemokines [23] . Hence, it is critical to identify the role of liver stromal cells in this process. Therefore, the aim of this study was to examine the possible mechanism underlying hepatic MDSC accumulation and to determine whether the liver stromal microenvironment regulates this process.
We prepared immortalized liver stromal cells to mimic the hepatic microenvironment and demonstrated the contribution of liver stromal cells to MDSC accumulation in a hepatoma-bearing mouse model. Our present study suggested a critical role for liver stromal cells in hepatic MDSC accumulation.
Materials and methods

Animals and cell lines
The Animal Care and Use Committee of Peking University People's Hospital approved all animal experiments. Female 6-week-old BALB/c mice (Vital River Laboratory Animal Technology Co., Ltd, Beijing, China) were used and housed in specific pathogen-free (SPF) animal facilities in our hospital. Animal experiments were performed using gender-and agematched controls. A hepatoma cell line (H22 cell) in a BALB/c background was maintained in liquid nitrogen until use.
Liver stromal cells were obtained and identified as described previously [24, 25] . Briefly, liver tissue was obtained from newly born mice at postnatal day 5, washed in sterile cold phosphate-buffered saline (PBS), cut into 1$2 mm 3 pieces, placed at the bottom of a cell-culture plate and cultured in RPMI-1640 medium supplemented with 20% fetal bovine serum (FBS). Half the culture medium was replaced each week. After several weeks of culture, fast-growing adherent cells were harvested and contaminating CD11b 1 macrophages were eliminated using anti-CD11b microbeads according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). These cells, designated as liver stromal cells (LS), were expanded for the following experiments.
Animal treatment
Mice were treated according to the animal treatment scheme as indicated in Fig. 1 . Tumour sizes were recorded every other day beginning 3 days after cell inoculation. Tumour volumes were estimated using the following formula: (length 3 width 2 )/2.
Blood sample collection
All mice received isoflurane anaesthaesia before experiments. Peripheral blood was then collected from the orbital sinus into heparinized tubes.
Isolation of splenocytes
Mouse spleens were isolated and minced in prechilled sterile PBS, followed by filtration through a 70-lm-cell strainer (BD Biosciences, San Diego, CA, USA). Red blood cells were removed using lysing buffer (BD Falcon   TM ).
Isolation of liver mononuclear cells (MNCs)
Hepatic MNCs were harvested as described previously [26] , with slight modifications. Briefly, mice livers were dissected from the body, cut into pieces, minced in PBEB buffer [2% bovine serum albumin (BSA) 0.5% mM ethylenediamine tetraacetic acid (EDTA) PBS] and filtered through a 70-lm cell strainer. Liver-infiltrated immune cells were enriched via discontinuous Percoll (GE Healthcare, Chicago, IL, USA) density gradient centrifugation and centrifuged at 500 g for 20 min at room temperature. Liver-infiltrated immune cells are at the interface of the 40 and 80% Percoll layers. Cells were harvested, washed, infiltrated with 70-lm cell strainer and resuspended in PBEB buffer for further analysis.
Isolation of pulmonary-infiltrated cells
Pulmonary-infiltrated immune cells were isolated as described above for the isolation of liver-infiltrated immune cells.
Isolation of bone marrow cells
Mouse bone marrow cells were isolated as described previously. Briefly, the femora and tibiae of all mice were dissected aseptically from the surrounding muscular tissue. Each of the marrow cavities was flushed with 10 ml of sterile cold PBS using a syringe and then washed with PBEB buffer at 300 g for 10 min at 48C. The cells were suspended in PBEB buffer and passed through a 70-lm-cell strainer to remove tissue debris.
A novel mechanism of MDSCs accumulation 
Flow cytometry
Fluorescence-activated cell sorting (FACS) analysis was performed according to the company's protocol. Detailed information on the antibodies used is presented in Supporting information, Table S1 . The data were recorded using CellQuest software (BD Biosciences) and analysed using FlowJo software version 9.3.2 (Tree Star, Ashland, OR, USA).
Purification of MDSCs and T cell proliferation assay
MDSCs were isolated and purified using mouse MDSC isolation kits (provided by Miltenyi Biotec), according to the manufacturer's protocol. The purity of the isolated MDSCs was assessed by FACS analysis. The immunosuppressive function of MDSCs was identified using a T cell proliferation assay. Briefly, carboxyfluorescein succinimidyl ester (CFSE)-labelled T cells were cultured with MDSCs at ratios (MDSCs/T) of 0 : 1, 1 : 1, 2 : 1 and 3 : 1 in the presence of CD3 (5 lg/ml) and CD28 (2 lg/ml) antibodies for 60 h, followed by FACS analysis.
In-vivo migration assay
For adoptive transfer, purified MDSCs were labelled with 2 lM CFSE and transferred adoptively via the caudal vein at 5 3 10 6 cells/mouse. Three hours later, the mice were killed. Single-cell suspensions from the liver, spleen, lung, bone marrow and blood were prepared as described above. and tumour-bearing mice (right) based on the staining of frozen sections for CD11b/Gr-1 (green) and 4,6-diamidino-2-phenylindole (DAPI) (blue). Scale bar, 100 lm. *P < 0Á05; **P < 0Á01; ***P < 0Á001. Student's t-test.
The cells were surface-labelled with anti-CD11b and antigranulocyte-differentiation antigen-1 (Gr-1), followed by flow cytometric analysis. Briefly, CD11b 
Biophotonic imaging of mice
Purified MDSCs were labelled with 10 lg of 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindotricarbocyanine iodide (DiR) dye in 2 ml of prewarmed (378C) PBS, followed by intravenous (i.v.) injection at 5 3 10 6 cells/mouse. The anaesthetized mice were imaged using a Caliper IVIS Spectrum series system (Caliper Life Sciences, PerkinElmer Inc., MA, USA) with a 745-nm excitation filter and an 800-nm emission filter. The optical intensity observed in each mouse was normalized to the background photon flux, which was defined using a mouse that received PBS. In addition, tumour nodules were excised and imaged in vitro. We analysed data using LIVINGIMAGE software (Caliper Life Sciences, Waltham, MA, USA).
Preparation of conditioned culture medium
Tumour supernatant (TSN) was prepared as described in our previous study [27] . Liver stromal cells conditioned medium was also prepared. Briefly, liver stromal cells were seeded at approximately 70% confluence, the supernatant was aspirated and the RPMI-1640 culture medium was replaced with 10% FBS. The cells were cultured for an additional 48 h in RPMI-1640 with 10% FBS. The supernatant was harvested and used as stromal cell supernatant for further study. In some cases, liver stromal cells were exposed to TSN for 48 h before collecting the cells and culture supernatant.
Gene expression analysis using gene microarrays
Liver stromal cells with or without TSN treatment were collected for RNA extraction. RNA samples were extracted from three independent experiments using TRIzol Reagent (Thermo Fisher Scientific Inc., Fremont, CA, USA), according to the manufacturer's instructions, and then pooled. The gene expression differences between the two groups were analysed by Affymetrix Mouse Gene 1.0 Array (Affymetrix, Santa Clara, CA, USA). Only those genes that were up-or down-regulated at least fivefold were included in the analysis. First, gene ontology (GO) analysis was applied to analyse the main function of the differential expression genes according to Gene Ontology, the key functional classification of the NCBI (National Center for Biotechnology Information, Bethesda, MD, USA), which can organize genes into hierarchical categories and uncover the gene regulatory network on the basis of biological process and molecular function. Specifically, two-sided Fisher's exact test and v 2 test were used and a P-value < 0Á001 was considered significant between two groups. We used Pathway analysis to determine the significant pathway of the differential genes according to the KEGG (Kyoto Encyclopedia of Genes and Genomes) database. The two-sided Fisher's exact test and v 2 test were used and a P-value < 0Á01 was considered significant between two groups. Pathway-Net analysis was then applied to determine the interaction net of the significant pathways of the differential expression genes according to the KEGG database. Finally, a gene-gene interaction network was constructed based on the data of differentially expressed genes. The considered evidence is the source of the interaction database from KEGG.
In-vitro chemotaxis assay
The in-vitro migration of MDSCs was examined using 24-well plates and Transwell cell culture inserts (8Á0-lm pore size) (Costar Corning, Cambridge, MA, USA) in triplicate experiments [8] . Conditioned medium from liver stromal cells and tumour cells was prepared, and 500 ll was added to the lower chamber of the culture system. Neutralizing monoclonal antibodies (mAbs) against monocyte chemotactic protein-1 (MCP-1) (200 ng/ml; eBioscience, San Diego, CA, USA) and stromal-derived factor-1 (SDF-1) (500 ng/ml; Peprotech, Rocky Hill, NJ, USA) (eBioscience) were added to the medium. Three hours later, purified MDSCs were suspended in 100 ll RPMI-1640 with 2% FBS and seeded in the upper chamber at 1Á0 3 10 6 cells/well, followed by 3 h incubation. The Transwell chambers were then removed, and the cells in the lower chamber were collected, washed, stained with antibodies against Gr-1 and CD11b and analysed via flow cytometry. MDSC migration towards culture medium alone was used as a negative control. MDSCs that migrated to the lower chamber were counted using Trucount TM Tubes (BD Biosciences Company, San Jose, CA, USA).
Real-time polymerase chain reaction (PCR)
Total RNA was extracted from 5 3 10 6 cells using TRIzol Reagent. The fold changes in expression are presented as described previously [28] . Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control, and the specific primers used are listed in Supporting information, Table S2 .
In-vivo neutralization assay
A total of 4 3 10 5 H22 cells were inoculated subcutaneously (s.c.) to obtain murine models of HCC. In some experiments, the mice were inoculated s.c. with H22 cells and 4 3 10 5 liver stromal cells. Functional neutralizing antibodies against MCP-1 (eBioscience) and SDF-1 (Peprotech) were administered at 2 mg/kg body weight via intraperitoneal (i.p.) injection every other day for 2 weeks. Simultaneously, tumour sizes were monitored using a digital caliper. Tumour-infiltrated lymphocytes were isolated and evaluated via flow cytometry.
Statistical analysis
Student's t-test was used to evaluate the significance of between the groups using SPSS version 17.0 software (SPSS Inc., Chicago, IL, USA). All P-values were two-sided, and P < 0Á05 was accepted as statistically significant. Data shown were analysed with GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA).
Results
Elevated hepatic MDSCs accumulated in hepatomabearing mice
In accordance with previous studies, at 2 weeks after H22 cell inoculation we observed a significant increase in the frequency and absolute numbers of CD11b 
Gr-1
1 cells in the bone marrow, spleen and peripheral blood of tumourbearing mice using flow cytometry (Fig. 1a) . Strikingly, a higher frequency and numbers of infiltrated CD11b
cells were also observed in the liver tissue of tumourbearing animals (Fig. 1a-c) . The intra-hepatic infiltration of CD11b 1 and Gr-1 1 cells was confirmed further by immunofluorescence staining with frozen sections from tumour mice and naive mice (Fig. 1d ).
Purified MDSCs suppressed T cell proliferation
Gr-1 1 cells were isolated from the bone marrow of tumour-bearing mice, as described in Methods. The purity was consistently greater than 90% in all samples as determined by FACS analysis (Fig. 2a) . To demonstrate the immunosuppressive capacity of these myeloid cells, we cocultured the purified MDSCs with CFSE-labelled splenocytes in the presence of CD3 and CD28 antibodies. All the tested myeloid cells potently suppressed the proliferation of CD4 1 T and CD8 1 T cells, indicating that these cells were functional MDSCs (Fig. 2b) .
Adoptively transferred MDSCs accumulate in the liver
Because tumour-induced haematopoiesis does not occur predominantly in the liver (Supporting information, Fig.  S1 ), and because MDSCs from the spleen home to the liver [13] , we examined whether MDSCs originating from the bone marrow could migrate to the liver. To this end, we isolated MDSCs from the bone marrow of tumour-bearing mice, labelled these cells with CFSE and then injected the purified MDSCs i.v. into recipient mice. Three hours after adoptive transfer, we analysed the CFSE 1 cells in the circulation and in organs. The results indicated that adoptively transferred MDSCs accumulated primarily in the liver, as determined by FACS analysis (Fig. 3a) . We observed greater numbers of MDSCs in the livers of tumour-bearing mice than in those of naive mice (Fig. 3b) . MDSC accumulation was increased slightly in the spleens of tumour-bearing mice compared with naive mice, although the spleen is an important site of MDSC accumulation in naive mice (Fig.  3b) .
To confirm these findings further, purified MDSCs were labelled with DiR, a lipophilic fluorescent dye, and injected i.v. into both naive and tumour-bearing mice for live imaging analysis. Consistent with the results from FACS analysis, we observed significant optical intensity in the livers of the recipients after cell transfer (Fig. 3c,d ), indicating that MDSCs from the bone marrow of tumour-bearing mice accumulated predominantly in the liver after adoptive transfer.
Liver stromal cells exhibit a unique chemokine expression profile that is modulated by the milieu of the tumour microenvironment
We assessed whether and how the hepatic microenvironment regulates MDSC accumulation in the liver. Liver stromal cells were prepared to mimic the hepatic microenvironment, as described above. We analysed the expression of inflammatory factors in liver stromal cells with or without treatment with TSN by microarray (Fig.  4a) . We found that a total of 1912 differential genes, including 1143 genes up-regulated and 769 down-regulated genes, had changed the level of expression after TSN treatment. As illustrated in Fig. 4a , we can see up-regulated expression of multiple genes in the chemokine family, including CCL1, CCL2 (MCP-1), CCL3, CCL4, CCL5, CCL6, CCL9, CCL12, CCL25, CXCL2, CXCL10 and CXCL12 (SDF-1) and down-regulated expression of multiple genes of collagens. Pathway analysis revealed that upregulated genes were associated with several functions, including cytokine-cytokine receptor interaction, Janus kinase-signal transducer and activator of transcription 1 (JAK-STAT) signalling pathway and T cell receptor signalling pathway. Down-regulated genes were associated with several functions, including the mitogen-activated protein kinase (MAPK), Wnt and p53 signalling pathways. The migration and accumulation of MDSCs is often promoted by proinflammatory factors such as IL-6, transforming growth factor (TGF)-b, PEG2, MCP-1 et al.; we confirmed cytokine and chemokine expression in liver stromal cells by quantitative-PCR. The hepatoma cell line had low levels of MCP-1 and M-CSF expression. Several cytokines, including MCP-1, SDF-1, M-CSF, vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and TGF-b were found to be expressed in liver stromal cells, while MCP-1, SDF-1, M-CSF and TGF-b expression in liver stromal cells were increased after TSN treatment (Fig. 4b) .
Liver stromal cells play a role in MDSCs accumulation into the liver and tumour site
Next, we assessed whether and how the liver stromal microenvironment contributes to hepatic MDSCs accumulation. Animals were treated according to animal treatment scheme 3 in Picture 1. Liver stromal cells were co-transplanted s.c. with hepatoma cells. Two weeks later, DiR-labelled MDSCs were injected i.v. into these tumour-bearing mice for live imaging analysis. As shown in Fig. 5a , tumour mice cotransplanted with H22 cells and liver stromal cells displayed higher levels of signal intensity in the liver (Fig. 5a,c, left) and also at the tumour site (Fig. 5b,c, right) . Moreover, in accordance with the higher level of MDSCs in the liver and tumour tissue, these mice showed more rapid tumour growth than those administered with tumour cells alone (Fig. 5d) , indicating that liver stromal cells may participate in MDSCs migration and accumulation after exposure to the milieu of the tumour microenvironment.
Blocking MCP-1 and SDF-1 reduced MDSCs migration and accumulation
To confirm further the above hypothesis, we attempted to block the effects of MCP-1 and SDF-1 using specific neutralizing antibodies. First, as described in the Materials and methods section, we prepared conditioned culture medium for in-vitro migration experiments using the Transwell culture system. MDSCs migrated to the lower chamber were counted (Fig. 6a) . As expected, supernatant from liver stromal cells promoted MDSC migration compared with RPMI-1640 culture medium and TSN in vitro. Interestingly, supernatant from TSN-treated liver stromal cells enhanced MDSC migration in vitro. Antibodies against MCP-1 or SDF-1 suppressed the migration of the MDSCs towards the liver stromal cells (Fig. 6b) .
Next, mice were treated according animal treatment scheme 4. Specific neutralizing antibodies against MCP-1 and SDF-1 were injected i.p. at 2 mg/kg body weight every other day from days 3 to 15 following tumour cell transplantation. During this (Fig. 7a) and MDSC infiltration in the tumour tissue was decreased due to treatment with neutralizing antibodies (Fig. 7b,c) . However, in the group of mice that were injected with H22 cells alone, neutralizing antibodies failed to affect tumour growth (Fig. 7b,c) , and the frequencies of MDSCs infiltrated in tumour were similar between the mice treated with antibodies and PBS. Thus, we propose that liver stromal cells contribute to tumour growth by promoting MDSC migration and infiltration, and that these effects are mediated by MCP-1 and SDF-1.
Discussion
The frequency of hepatic MDSCs was elevated in tumourbearing individuals, but the potential mechanisms are not understood fully. The present study indicated that tumouractivated liver stromal cells promote MDSC migration and accumulation in the liver via chemokines such as MCP-1 and SDF-1. Our study suggests a novel regulatory mechanism of hepatic MDSCs accumulation. Recently, MDSCs migration into liver sites has attracted increased interest. The liver is a newly described site for MDSCs accumulation, especially in tumour mice [12, 13] . The infiltration of MDSCs into tumour tissue has been studied in the past few years due to their immunosuppressive function in anti-tumour responses [29] .
Chemotactic function related
Cytokines and chemokines MDSCs are immature myeloid cells with strong immunosuppressive functions. We have shown that the relative and absolute number of MDSCs in the liver increased in s.c. hepatoma-bearing mice, in keeping with previous work [12] . MDSCs accumulation in the liver occurs as the tumour grows in mice with transplanted tumours, as well as in late stages of tumour growth in mice with chemically induced hepatocarcinogenesis [12] . High levels of MDSCs also correlate with tumour progression in HCC patients [30] . Therefore, it is worth investigating whether these MDSCs migrated from other organs into the liver.
The development and progression of HCC is a multistage process, and the hepatic microenvironment plays a critical role in tumour initiation and progress. The stromal components of the microenvironment include mainly immune cells, macrophages and fibroblasts. to mimic the hepatic microenvironment. Our data suggested the interaction of stromal cells with tumour cells and the tumour-infiltrated immune cells. The definite mechanisms underlining these interactions will be explored in a future study. In a previous study, adoptively transferred MDSCs accumulated favourably in the liver in mice with s.c. transplanted tumours, irrespective of the tumour type [13] . Interestingly, co-transplantation of liver stromal cells and hepatoma cells increased MDSCs migration into the liver. MDSC accumulation at tumour sites was also higher in mice co-transplanted with liver stromal cells and tumour cells. This result is consistent with the 'seed and soil' theory that liver stromal cells are not only active bystanders, but play an important role during tumour development [31] . However, transplantation of liver stromal cells alone did not increase the levels of MDSCs in the liver and circulation. Conversely, decreasing the level of MDSCs can limit the development of HCC [32] . Taken together, the present study suggests that liver stromal cells may be valuable targets for decreasing hepatic MDSCs.
MDSC migration is associated with chemokines and/or cytokines via autocrine or paracrine signaling. Thus, several factors from tumour-activated liver stromal cells may be associated with MDSC accumulation in the liver. MCP-1 (CCL2) and SDF-1 (CXCL12) are the two most dominant factors that are expressed highly in liver stromal cells but not in hepatoma cells. MCP-1 has been shown to be involved in MDSCs migration [10, 33, 34] . Liver stromal cell-derived MCP-1 was able to mediate HCC cell migration and invasion [35] . Given the immunosuppressive The average number of MDSCs in the lower chamber from three duplicate wells was counted after the indicated treatment. The data shown are representative of four independent experiments. P < 0Á05; **P < 0Á01; ****P < 0Á0001. Student's t-test. tumour-conditioned medium in vitro. Meanwhile, MCP-1 expression levels in the liver tissue of tumour-bearing mice increased gradually with tumour growth (data not shown). HCC progression results from cross-talk between tumour cells and various stromal cells, and combined immunotherapy approaches offer far greater benefits for HCC treatment [40] . The current study provides evidence of a novel regulatory mechanism of hepatic MDSCs accumulation mediated by liver stromal cells. In summary, this study suggests a novel regulatory mechanism by which liver stromal cells promote hepatic MDSCs accumulation. Tumour-associated liver stromal cells contribute to MDSCs accumulation and promote tumour growth. Understanding the cross-talk between the liver stroma and MDSCs in HCC may provide a promising breakthrough for future immunotherapeutic strategies.
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Additional supporting information may be found in the online version of this article at the publisher's web-site: Fig. S1 . Representative images showed myeloid-derived suppressor cell (MDSC) infiltration in frozen liver sections from naive (left) and tumour-bearing mice (right) stained with CD11b/granulocyte-differentiation antigen-1 (Gr-1) (green) and 4,6-diamidino-2-phenylindole (DAPI) (blue). Scale bar, 100 lm. Fig. S2 . Fluorescence activated cell sorter (FACS) analysis of subpopulations of common haematopoietic stem cell and common myeloid precursors in bone marrow, spleens and liver. Fig. S3 . Gating strategy of myeloid-derived suppressor cell (MDSC) after adoptive transfer. Fig. S4 . mRNA levels of chemokines and cytokines expression in liver stromal cells were tested by reverse transcription-polymerase chain reaction (RT-PCR). Fig. S5 . Graphic describing the preparation of the conditioned culture medium for the in-vitro assay. Table S1 Antibodies used for fluorescence activated cell sorter (FACS) analysis. Table S2 Primers used for reverse transcription-polymerase chain reaction (RT-PCR) amplification.
